Oppenheimer Sticks to Their Hold Rating for Agios Pharma

By Carrie Williams

In a report released yesterday, Leah R. Cann from Oppenheimer maintained a Hold rating on Agios Pharma (NASDAQ: AGIO). The company’s shares closed yesterday at $86.02, close to its 52-week high of $89.33.

R. Cann commented:

“While we have not modeled any revenue impact from AG-270 to either Agios or Celgene by 2022, we believe that AG-270 could be an important value driver for Agios and Celgene. AG-270 is a novel compound in the field of synthetic lethality, and has the potential to address large patient populations. We are not making any changes to our outlook at this time, but we continue to watch the timing of the program closely.”

According to TipRanks.com, Cann is a 4-star analyst with an average return of 11.7% and a 49.3% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.

Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $89.33.

The company has a one-year high of $89.33 and a one-year low of $45.11. Currently, Agios Pharma has an average volume of 585.3K.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGIO in relation to earlier this year. Most recently, in February 2018, Kaye Foster-Cheek, a Director at AGIO bought 2,200 shares for a total of $104,126.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in applying scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. Its products include IDH1 AND IDH2, PKR, II D-2 hydroxyglutaric aciduria, AG-221 and AG-120.